



CNMV (Spanish Securities and Exchange Commission)
Markets Directorate General
C/ Edison 4
28006 Madrid

Madrid, 27 July 2023

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following

OTHER RELEVANT INFORMATION

It is hereby informed that, under the authorization granted by the General Shareholders' Meeting held on May 31, 2023 for the derivative acquisition of treasury shares, Pharma Mar, S.A. (the “**Company**”) has agreed in its Board of Director’s Meeting held today to carry out the acquisition of Company’s treasury shares (the “**Acquisition of Treasury Shares**”).

The purpose of the Acquisition of Treasury Shares is the Company's interest in having the capacity to act in the performance of transactions in its own shares in order, if appropriate, to undertake potential corporate transactions. Notwithstanding the foregoing, given that such purpose does not comply with the provisions for buy-back programmes and stabilisation of the Commission Delegated Regulation (EU) 2016/1052, it is the Issuer's intention that the operation of the Acquisition of Treasury Shares shall be subject to the limits, procedures and other considerations that the applicable legal regulations impose on buy-back programmes and stabilisation.

The Acquisition of Treasury Shares shall be subject to the following limits:

- (a) Maximum number of shares and cash amount: the Acquisition of Treasury Shares will affect a maximum of 540,000 shares, representing approximately 2.94% of the Company's share capital on the date of this announcement, and its maximum cash amount amounts to €15,000,000.00.
- (b) Duration: The Acquisition of Treasury Shares will have a maximum duration of six (6) months, beginning on August 1, 2023 and remaining in effect until January 31, 2024. Notwithstanding the foregoing, the Company may terminate the Acquisition of Treasury Shares if, prior to the effective date, it had acquired the maximum number of shares or the maximum cash amount authorized by the Board of Directors referred to in section (a) above or if any other circumstance that so advises occurs.

The Acquisition of Treasury Shares will be lead managed by JB CAPITAL MARKETS, SOCIEDAD DE VALORES, S.A.U., who will carry out the operations completely independently of the Company.

Likewise, to enable the Acquisition of Treasury Shares, the Company has agreed to temporarily suspend, with effect from close of market on July 31, 2023, the liquidity contract signed with JB CAPITAL MARKETS, SOCIEDAD DE VALORES, S.A.U., which entered into force on June 28, 2021 and whose operations were effective from July 13, 2021, as communicated to the market through an Other Relevant Information of this last date (registration number 10,583).

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com